Monographie - Etoposide phosphate - Stabilis 4.0

Son güncelleme :
29/10/2024

kanser ilaç

Etoposide phosphate

Enjeksiyon

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Etopofos	Arjantin, Avusturya, Danimarka, Finlandiya, İsveç, Norveç
Etopophos	Almanya, Amerika Birleşik Devletleri, Belçika, Bulgaristan, Büyük Britanya, Fransa, Güney Afrika Cumhuriyeti, Hollanda, İsrail, İsviçre, Lüksemburg, Polonya, yeni Zelanda
Nexvep	Brezilya
Toposar	Amerika Birleşik Devletleri

Kaynaklar

Enjeksiyon

Kaynaklar : Etoposide phosphate

	tip	yayın
1410	Dergi	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1411	Dergi	Zhang Y, Trissel LA. Physical and chemical stability of etoposide phosphate solutions. J Am Pharm Assoc 1999 ; 39: 146-150.
1423	Dergi	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1606	Dergi	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	Dergi	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Dergi	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Dergi	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Dergi	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Dergi	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Dergi	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3644	Laboratuar	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3655	Laboratuar	Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2016
3838	Laboratuar	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4102	Dergi	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.

Mentions Légales